JPWO2022102731A1 - - Google Patents
Info
- Publication number
- JPWO2022102731A1 JPWO2022102731A1 JP2022562190A JP2022562190A JPWO2022102731A1 JP WO2022102731 A1 JPWO2022102731 A1 JP WO2022102731A1 JP 2022562190 A JP2022562190 A JP 2022562190A JP 2022562190 A JP2022562190 A JP 2022562190A JP WO2022102731 A1 JPWO2022102731 A1 JP WO2022102731A1
- Authority
- JP
- Japan
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2026005611A JP2026067904A (ja) | 2020-11-13 | 2026-01-16 | Ep4拮抗薬と免疫チェックポイント阻害物質との併用によるがん治療 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020189152 | 2020-11-13 | ||
| JP2020189152 | 2020-11-13 | ||
| JP2020211006 | 2020-12-21 | ||
| JP2020211006 | 2020-12-21 | ||
| JP2021006828 | 2021-01-20 | ||
| JP2021006828 | 2021-01-20 | ||
| PCT/JP2021/041650 WO2022102731A1 (ja) | 2020-11-13 | 2021-11-12 | Ep4拮抗薬と免疫チェックポイント阻害物質との併用によるがん治療 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2026005611A Division JP2026067904A (ja) | 2020-11-13 | 2026-01-16 | Ep4拮抗薬と免疫チェックポイント阻害物質との併用によるがん治療 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPWO2022102731A1 true JPWO2022102731A1 (cg-RX-API-DMAC7.html) | 2022-05-19 |
| JP7816164B2 JP7816164B2 (ja) | 2026-02-18 |
Family
ID=81602339
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022562190A Active JP7816164B2 (ja) | 2020-11-13 | 2021-11-12 | Ep4拮抗薬と免疫チェックポイント阻害物質との併用によるがん治療 |
| JP2026005611A Pending JP2026067904A (ja) | 2020-11-13 | 2026-01-16 | Ep4拮抗薬と免疫チェックポイント阻害物質との併用によるがん治療 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2026005611A Pending JP2026067904A (ja) | 2020-11-13 | 2026-01-16 | Ep4拮抗薬と免疫チェックポイント阻害物質との併用によるがん治療 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20230390303A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4245301A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7816164B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230107228A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022102731A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20200352906A1 (en) * | 2018-02-05 | 2020-11-12 | Shenzhen Ionova Life Science Co., Ltd. | Heterobicyclic Carboxylic Acids for Treating Cancer or Inflammatory Diseases |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017014177A1 (ja) * | 2015-07-17 | 2017-01-26 | 凸版印刷株式会社 | 健康状態の評価方法及び抗がん剤に対する長期奏功性の予測方法 |
| WO2018008711A1 (ja) * | 2016-07-07 | 2018-01-11 | 小野薬品工業株式会社 | Ep4拮抗薬と免疫チェックポイント阻害薬を含んでなる組み合わせ |
| WO2019117269A1 (ja) * | 2017-12-13 | 2019-06-20 | 国立大学法人広島大学 | 膵がんの検出を補助する方法 |
| WO2020111018A1 (ja) * | 2018-11-27 | 2020-06-04 | 小野薬品工業株式会社 | 免疫チェックポイント阻害薬およびfolfirinox療法との併用によるがん治療 |
Family Cites Families (79)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ517202A (en) | 1999-08-24 | 2004-05-28 | Medarex Inc | Human CTLA-4 antibodies and their uses |
| WO2001062708A1 (fr) | 2000-02-22 | 2001-08-30 | Ono Pharmaceutical Co., Ltd. | Derives d'acide benzoique, procede de production desdits derives, et medicament contenant ces derives comme principe actif |
| WO2002016311A1 (en) | 2000-08-22 | 2002-02-28 | Ono Pharmaceutical Co., Ltd. | Carboxylic acid derivatives, process for producing the same and drugs containing the same as the active ingredient |
| WO2002020462A1 (en) | 2000-09-01 | 2002-03-14 | Ono Pharmaceutical Co., Ltd. | Benzoic acid derivatives and drugs containing the same as the active ingredient |
| HN2001000224A (es) | 2000-10-19 | 2002-06-13 | Pfizer | Compuestos de imidazol condensado con arilo o heteroarilo como agentes anti - inflamatorios y analgesicos. |
| GB0031295D0 (en) | 2000-12-21 | 2001-01-31 | Glaxo Group Ltd | Naphthalene derivatives |
| GB0031302D0 (en) | 2000-12-21 | 2001-01-31 | Glaxo Group Ltd | Napthalene derivatives |
| GB0031315D0 (en) | 2000-12-21 | 2001-02-07 | Glaxo Group Ltd | Indole derivatives |
| MXPA04001253A (es) | 2001-08-09 | 2004-06-03 | Ono Pharmaceutical Co | Derivados de acidos carboxilicos y agente farmaceutico que comprende los mismos como ingrediente activo. |
| JP2005532291A (ja) | 2002-04-12 | 2005-10-27 | ファイザー株式会社 | 抗炎症薬および鎮痛薬としてのピラゾール化合物 |
| MXPA04009961A (es) | 2002-04-12 | 2004-12-13 | Pfizer | Compuestos de imidazol como agentes anti-inflamatorios y analgesicos. |
| CA2485485A1 (en) | 2002-05-23 | 2003-12-04 | Theratechnologies Inc. | Antagonistic peptides of prostaglandin e2 receptor subtype ep4 |
| CN100408570C (zh) | 2003-01-29 | 2008-08-06 | 阿斯特兰德英国有限公司 | Ep4受体拮抗剂 |
| CA2536870C (en) | 2003-09-03 | 2009-10-27 | Pfizer Inc. | Phenyl or pyridyl amide compounds as prostaglandin e2 antagonists |
| GB0324269D0 (en) | 2003-10-16 | 2003-11-19 | Pharmagene Lab Ltd | EP4 receptor antagonists |
| EP1697337A2 (en) | 2003-12-22 | 2006-09-06 | Astellas Pharma Inc. | Ornithine derivatives as prostaglandin-e2-agonists or antagonists |
| KR20070006890A (ko) | 2004-05-04 | 2007-01-11 | 화이자 인코포레이티드 | 오르토 치환된 아릴 또는 헤테로아릴 아마이드 화합물 |
| AU2005238291A1 (en) | 2004-05-04 | 2005-11-10 | Pfizer Inc. | Substituted methyl aryl or heteroaryl amide compounds |
| EP1765379A4 (en) | 2004-06-17 | 2009-05-27 | Transform Pharmaceuticals Inc | PHARMACEUTICAL CO-CRYSTAL COMPOSITIONS AND RELEVANT USE METHOD |
| EP3530736A3 (en) | 2005-05-09 | 2019-11-06 | ONO Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
| ATE533766T1 (de) | 2005-05-19 | 2011-12-15 | Merck Canada Inc | Chinolinderivate als ep4-antagonisten |
| KR101704734B1 (ko) | 2005-07-01 | 2017-02-09 | 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체 |
| JP5244091B2 (ja) | 2006-04-24 | 2013-07-24 | メルク カナダ インコーポレイテッド | Ep4受容体アンタゴニストとしてのインドールアミド誘導体 |
| CA2654811A1 (en) | 2006-06-12 | 2007-12-21 | Merck Frosst Canada Ltd. | Indoline amide derivatives as ep4 receptor ligands |
| AU2007283404B2 (en) | 2006-08-11 | 2013-04-18 | Merck Canada Inc. | Thiophenecarboxamide derivatives as EP4 receptor ligands |
| CA2679175C (en) | 2007-02-26 | 2015-01-13 | Merck Frosst Canada Ltd. | Indole and indoline cyclopropyl amide derivatives as ep4 receptor antagonists |
| CN101636385B (zh) | 2007-03-26 | 2012-09-05 | 默克弗罗斯特加拿大有限公司 | 作为ep4受体拮抗剂的萘和喹啉磺酰脲衍生物 |
| KR20090122931A (ko) | 2007-03-26 | 2009-12-01 | 아스테라스 세이야쿠 가부시키가이샤 | 오르니틴 유도체 |
| PT2170959E (pt) | 2007-06-18 | 2014-01-07 | Merck Sharp & Dohme | Anticorpos para o receptor humano de morte programada pd-1 |
| EP2172447A4 (en) | 2007-07-03 | 2011-08-24 | Astellas Pharma Inc | amide |
| ES2518919T3 (es) | 2008-05-14 | 2014-11-05 | Astellas Pharma Inc. | Derivados del ácido 4-(Indol-7-ilcarbonilaminometil)ciclohexanocarboxílico como antagonistas del receptor EP4 útiles para el tratamiento de la insuficiencia renal crónica o la nefropatía diabética |
| CN102149384B (zh) | 2008-08-14 | 2014-08-20 | 南京奥昭生物科技有限公司 | 作为ep4受体拮抗剂的杂环酰胺衍生物 |
| MX2011003166A (es) | 2008-09-25 | 2011-04-27 | Merck Frosst Canada Ltd | Derivados de sulfonilurea beta-carbolina como antagonistas del receptor ep4. |
| WO2012039972A1 (en) | 2010-09-21 | 2012-03-29 | Eisai R&D Management Co., Ltd. | Pharmaceutical composition |
| ES2537017T3 (es) | 2010-09-29 | 2015-06-01 | Nb Health Laboratory Co. Ltd. | Anticuerpo dirigido contra el receptor EP4 de la prostaglandina E2 humano |
| WO2012076063A1 (en) | 2010-12-10 | 2012-06-14 | Rottapharm S.P.A. | Pyridine amide derivatives as ep4 receptor antagonists |
| WO2012103071A2 (en) | 2011-01-25 | 2012-08-02 | Eisai R&D Management Co., Ltd. | Compounds and compositions |
| PL2729445T3 (pl) | 2011-07-04 | 2016-04-29 | Rottapharm Biotech Srl | Cykliczne pochodne aminowe jako antagoniści receptora EP4 |
| CA2860382C (en) | 2011-12-21 | 2017-09-12 | Allergan, Inc. | Compounds acting at multiple prostaglandin receptors giving a general anti-inflammatory response |
| WO2013096501A1 (en) | 2011-12-21 | 2013-06-27 | Allergan, Inc. | Compounds acting at multiple prostaglandin receptors giving a general anti-inflammatory response |
| CA2862266C (en) | 2011-12-27 | 2016-10-04 | Allergan, Inc. | Compounds acting at multiple prostaglandin receptors giving a general anti-inflammatory response |
| WO2013101598A1 (en) | 2011-12-27 | 2013-07-04 | Allergan, Inc. | Compounds acting at multiple prostaglandin receptors giving a general anti-inflammatory response |
| TWI572597B (zh) | 2012-06-29 | 2017-03-01 | 美國禮來大藥廠 | 二甲基-苯甲酸化合物 |
| AR091429A1 (es) | 2012-06-29 | 2015-02-04 | Lilly Co Eli | Compuestos de fenoxietil piperidina |
| UA115576C2 (uk) | 2012-12-06 | 2017-11-27 | Байєр Фарма Акцієнгезелльшафт | Похідні бензимідазолу як антагоністи ер4 |
| TW201443004A (zh) | 2013-02-15 | 2014-11-16 | Lilly Co Eli | 苯氧基乙氧基化合物 |
| TWI636046B (zh) | 2013-05-17 | 2018-09-21 | 美國禮來大藥廠 | 苯氧基乙基二氫-1h-異喹啉化合物 |
| CN105431416B (zh) | 2013-06-12 | 2019-01-08 | 科研制药株式会社 | 4-炔基咪唑衍生物和含有其作为有效成分的药物 |
| JP6200596B2 (ja) | 2013-12-17 | 2017-09-20 | イーライ リリー アンド カンパニー | ジメチル安息香酸化合物 |
| HUE035698T2 (en) | 2013-12-17 | 2018-05-28 | Lilly Co Eli | Phenoxyethyl ring amine derivatives and their activity as EP4 receptor modulator |
| TW201607943A (zh) | 2013-12-19 | 2016-03-01 | 拜耳製藥公司 | 作為ep4配體之新穎苯并咪唑衍生物 |
| WO2015113057A1 (en) | 2014-01-27 | 2015-07-30 | Allergan, Inc. | Antagonists acting at multiple prostaglandin receptors for the treatment of inflammation |
| TW201623277A (zh) | 2014-03-26 | 2016-07-01 | 安斯泰來製藥股份有限公司 | 醯胺化合物 |
| WO2016021742A1 (en) | 2014-08-07 | 2016-02-11 | Takeda Pharmaceutical Company Limited | Heterocyclic compounds as ep4 receptor antagonists |
| WO2016088903A1 (en) | 2014-12-05 | 2016-06-09 | Takeda Pharmaceutical Company Limited | Heterocyclic compounds |
| HUE052969T2 (hu) | 2015-01-09 | 2021-05-28 | Ono Pharmaceutical Co | Triciklusos spiro vegyület |
| JP6689297B2 (ja) | 2015-07-23 | 2020-04-28 | 武田薬品工業株式会社 | 複素環化合物 |
| CA3002144C (en) | 2015-10-16 | 2024-01-23 | Eisai R&D Management Co., Ltd. | Ep4 antagonists |
| CR20180323A (es) | 2015-11-20 | 2018-08-06 | Idorsia Pharmaceuticals Ltd | Derivados de indol n-sustituídos como moduladores de los receptores de pge2 |
| JP6269888B1 (ja) * | 2016-07-07 | 2018-01-31 | 小野薬品工業株式会社 | 医薬用途 |
| WO2018195123A1 (en) | 2017-04-18 | 2018-10-25 | Tempest Therapeutics, Inc. | Bicyclic compounds and their use in the treatment of cancer |
| KR102612140B1 (ko) | 2017-05-18 | 2023-12-08 | 이도르시아 파마슈티컬스 리미티드 | 피리미딘 유도체 |
| AR111808A1 (es) | 2017-05-18 | 2019-08-21 | Idorsia Pharmaceuticals Ltd | Derivados de pirimidina como moduladores del receptor de pge2 |
| PE20191787A1 (es) | 2017-05-18 | 2019-12-24 | Idorsia Pharmaceuticals Ltd | Derivados de indol n-sustituidos |
| EA201992676A1 (ru) | 2017-05-18 | 2020-05-06 | Идорсия Фармасьютиклз Лтд | Фенильные производные в качестве модуляторов pge2 рецепторов |
| US11325899B2 (en) | 2017-05-18 | 2022-05-10 | Idorsia Pharmaceuticals Ltd | Benzofurane and benzothiophene derivatives as PGE2 receptor modulators |
| JP7211358B2 (ja) | 2017-05-22 | 2023-01-24 | 小野薬品工業株式会社 | Ep4アンタゴニスト |
| CN108929281B (zh) | 2017-05-27 | 2021-12-24 | 华东师范大学 | 三氮唑类化合物及其合成方法和应用 |
| WO2019038156A1 (en) | 2017-08-22 | 2019-02-28 | Bayer Pharma Aktiengesellschaft | USE OF AN EP4 ANTAGONIST FOR THE TREATMENT OF ARTHRITIS |
| JP7159007B2 (ja) * | 2017-11-01 | 2022-10-24 | 小野薬品工業株式会社 | 脳腫瘍の治療のための医薬 |
| CN109836434B (zh) | 2017-11-27 | 2020-09-25 | 上海宇耀生物科技有限公司 | 噻吩并环类化合物及其合成方法和应用 |
| CN111936138B (zh) | 2018-02-05 | 2024-03-08 | 深圳市原力生命科学有限公司 | 作为ep4受体拮抗剂的杂二环化合物 |
| WO2019166022A1 (en) | 2018-03-02 | 2019-09-06 | Shenzhen Ionova Life Science Co., Ltd. | Heterobicyclic carboxylic acids and salts thereof |
| WO2019245590A1 (en) | 2018-06-18 | 2019-12-26 | Avista Pharma Solutions, Inc. | Chemical compounds |
| US20210315909A1 (en) | 2018-07-11 | 2021-10-14 | Arrys Therapeutics, Inc. | Polymorphic compounds and uses thereof |
| US11718582B2 (en) | 2018-07-12 | 2023-08-08 | Rottapharm Biotech S.R.L. | (R)-4-(1-(1-(4-(trifluoromethyl)benzyl)pyrrolidine-2-carboxamide)cyclopropyl)-benzoic acid as EP4 receptor antagonist |
| KR102861190B1 (ko) | 2019-01-22 | 2025-09-17 | 키테라 (쑤저우) 바이오-파마슈티컬스 컴퍼니 리미티드 | Pge2/ep4 신호 전달을 억제하기 위한 화합물, 이의 제조 방법, 및 이의 의약적 용도 |
| CA3128024A1 (en) | 2019-01-30 | 2020-08-06 | Avista Pharma Solutions, Inc. | Chemical compounds |
| EP3693359A1 (en) | 2019-02-08 | 2020-08-12 | Medibiofarma, S.L. | New n-benzyl-2-phenoxybenzamide derivatives as prostaglandin e2 (pge2) receptors modulators |
-
2021
- 2021-11-12 JP JP2022562190A patent/JP7816164B2/ja active Active
- 2021-11-12 EP EP21891976.9A patent/EP4245301A4/en active Pending
- 2021-11-12 KR KR1020237015423A patent/KR20230107228A/ko active Pending
- 2021-11-12 US US18/035,608 patent/US20230390303A1/en active Pending
- 2021-11-12 WO PCT/JP2021/041650 patent/WO2022102731A1/ja not_active Ceased
-
2026
- 2026-01-16 JP JP2026005611A patent/JP2026067904A/ja active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017014177A1 (ja) * | 2015-07-17 | 2017-01-26 | 凸版印刷株式会社 | 健康状態の評価方法及び抗がん剤に対する長期奏功性の予測方法 |
| WO2018008711A1 (ja) * | 2016-07-07 | 2018-01-11 | 小野薬品工業株式会社 | Ep4拮抗薬と免疫チェックポイント阻害薬を含んでなる組み合わせ |
| WO2019117269A1 (ja) * | 2017-12-13 | 2019-06-20 | 国立大学法人広島大学 | 膵がんの検出を補助する方法 |
| WO2020111018A1 (ja) * | 2018-11-27 | 2020-06-04 | 小野薬品工業株式会社 | 免疫チェックポイント阻害薬およびfolfirinox療法との併用によるがん治療 |
Non-Patent Citations (3)
| Title |
|---|
| CHAN, KELVIN ET AL., PLOS ONE, vol. Vol.9, No.10, e108749, JPN6025041505, 2014, pages 1 - 9, ISSN: 0005702720 * |
| GARON, EDWARD B ET AL., LANCET, vol. 384, JPN6025041504, 2014, pages 665 - 673, ISSN: 0005702721 * |
| 楊知明 ほか, 癌と化学療法, vol. 38, no. 6, JPN6025041503, 2011, pages 1021 - 1024, ISSN: 0005702722 * |
Also Published As
| Publication number | Publication date |
|---|---|
| US20230390303A1 (en) | 2023-12-07 |
| EP4245301A4 (en) | 2024-08-21 |
| TW202228674A (zh) | 2022-08-01 |
| JP7816164B2 (ja) | 2026-02-18 |
| KR20230107228A (ko) | 2023-07-14 |
| WO2022102731A1 (ja) | 2022-05-19 |
| EP4245301A1 (en) | 2023-09-20 |
| JP2026067904A (ja) | 2026-04-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR102020022030A2 (cg-RX-API-DMAC7.html) | ||
| BR102021017262B1 (pt) | Ferramenta de torque que usa cores para identificação | |
| BR102021013306B1 (pt) | Disposição introduzida em forno de pizza, com dispostivo de regulagem de altura da esteira com ajustes gradual escalonado | |
| BR102021010384B1 (pt) | Equipamento para limpeza e/ou teste de bicos injetores com alta pressão | |
| BR102021009961B1 (pt) | Sistema e método para aproveitamento da água de injeção dessulfatada de plataformas marítimas para utilização em squeezes de inibição | |
| BR102021007825B1 (pt) | Equipamento de entretenimento e contemplação visual por cabines rotacionais e com giro radial e axial de 360 graus, para instalação em coberturas de edificações, penhascos ou encostas de elevações geográficas abissais | |
| BR102021006565B1 (pt) | Máquina de acabamento de estradas e método para operar a mesma | |
| BR102021005700B1 (pt) | Selo irregular para redução de ruído em aeronaves | |
| BR102021005383B1 (pt) | Método de perfurar um furo de poço marítimo com circulação reversa de fluido sem uso de tubulares de riser de perfuração | |
| BR102021004908B1 (pt) | Equipamento gerador de dióxido de cloro com processamento em alta pressão em reator com três zonas de operação para tratamento de águas e efluentes | |
| BR102021003589B1 (pt) | Método para fabricar uma estrutura monolítica em formato de caixa para fuselagens e asas de aeronave usando um material prepreg de matriz de polímero reforçada com fibra | |
| BR102021003353B1 (pt) | Aerofólio compósito estrutural, aeronave e método de montagem de um aerofólio compósito estrutural | |
| BR102021002172B1 (pt) | Sistema de trem de pouso, métodos de retração e de implantação de um sistema de trem de pouso | |
| BR102021000474B1 (pt) | Aparelho de pino de medição, sistema de amortecimento multiator, e, conjunto de amortecedor de impacto | |
| BR102020026775B1 (pt) | Montagem de painel de malha de arame soldado e uma ou mais armações, e parede ou teto reforçado por uma ou mais montagens | |
| BR102020026454B1 (pt) | Membrana de nanocelulose bacteriana e seu uso como bolus em radioterapia | |
| BR102020026302B1 (pt) | Processo de produção de corante natural azul | |
| BR102020023974B1 (pt) | Revestimento de amarras para redução de arrasto longitudinal | |
| BR102020021170B1 (pt) | Composição, formulações orais e uso | |
| BR102020018864B1 (pt) | Grade de ventilação modular | |
| BR102020018483B1 (pt) | Dispositivo mecânico para arraste de cabeçote móvel para realização de furos, alargamentos, roscas com machos por intermédio de automatização em tornos mecânicos horizontais | |
| BR102020010912B1 (pt) | Aparelho compacto de eletrólise de baixo custo | |
| BR102020007524B1 (pt) | Sistema de montagem e controle de acumuladores em estações de trabalho | |
| BR102020005641B1 (pt) | Método integrado de cultura do peixe lambari-do-rabo-amarelo, camarão-da-amazônia e o peixe curimbatá | |
| BR102020004560B1 (pt) | Rotor eólico utilizando duplas-pás inteiriças para geração de potência |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20240902 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20251007 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20251127 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20251127 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20260106 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20260119 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7816164 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |